

United States Patent Office

In re patent application of: **Glaxo Group Limited**

International Application I No: **PCT/EP2003/007939**

International Filing Date: July 17, 2003 (17/07/2003)

Title: **TRANSGENIC ANIMAL MODELS OF HRV WITH HUMAN ICAM-1 SEQUENCES**

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH US 37 C.F.R. § 1.821-1.825 and under PCT Rule 13ter.1 (a) and (c)**


Sir:

In connection with a Sequence Listing submitted with the specification, the undersigned hereby states that:

1. the submission, filed herewith in accordance with US37 C.F.R. § 1.821 (g), does not include new matter;
2. the content of the paper copy as filed with the specification and the attached computer readable copy of the Sequence Listing, submitted in accordance with US37 C.F.R. § 1.821 (e) and (f), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted

14 Jan. 2005
Date



Virginia G. CAMPEN
Attorney for Applicant

GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1012
Facsimile: 919-483-7988